Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GNR-084
- Development stage
- Phase 2
- Lead developer
- AO GENERIUM
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
GNR-084 is a bispecific T-cell engager antibody that targets both the CD19 antigen on B cells and the CD3 antigen on T cells. By binding simultaneously to these two antigens, GNR-084 brings cytotoxic T lymphocytes into close proximity with malignant B cells, facilitating targeted cell-mediated cytotoxicity against cancerous B cells. The drug is being developed primarily for the treatment of refractory or relapsed B-cell precursor acute lymphoblastic leukemia (ALL). It is in Phase 1/2 clinical trials and utilizes an IgG-like bispecific format (BiMS). The originator and main developer is Generium Pharmaceuticals[2][3][4][5][6][8].
- Other names
- CD3/CD19 bispecific antibody
02
Targets
CD19 (B lymphocyte antigen CD19)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on GNR-084.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GNR-084.